A practitioner’s guide to the recombinant zoster vaccine: review of national vaccination recommendations

Parikh, Raunak; Widenmaier, Robyn; Lecrenier, Nicolas

doi:10.1080/14760584.2021.1956906

Cited by 25 publications

(27 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 88 The RZV vaccine was licensed as of 2018, and in 2021, it was recommended for use in the national vaccine schedule. 20 …”

Section: Resultsmentioning

confidence: 99%

“…Despite being licensed in 2006, ZVL has only been approved in fewer than 70 countries as of 2020. 20 It is only a part of the national vaccination schedule in handful of countries ( Table 1 and Table 2 ) and is reimbursed or funded by national health systems in only 8 countries. The adjuvanted recombinant vaccine RZV was licensed in 2017 and is approved in fewer than 40 countries.…”

Section: Discussionmentioning

confidence: 99%

“…The adjuvanted recombinant vaccine RZV was licensed in 2017 and is approved in fewer than 40 countries. 20 There is a disproportionately lower number of countries that have HZ vaccination programs among developing nations, and research on epidemiology and cost-effectiveness of HZ vaccination is very limited in these regions ( Table 2 ). Considerations for implementation of HZ vaccination include cost-effectiveness of vaccination and other public health concerns such as exogenous boosting as well as public perception, education, and awareness.…”

Section: Discussionmentioning

confidence: 99%

“…Germany and Spain). 20 Furthermore, the RZV vaccine can be administered with other non-HZ vaccines such as the inactivated influenza vaccine, PPSV23, and reduced antigen diphtheria-tetanus-acellular pertussis vaccine without affecting the immunogenicity of the other vaccines. 24 Contraindications to the RZV vaccine include hypersensitivity to active and excipient ingredients.…”

Section: Vaccine Administration and Special Considerationsmentioning

confidence: 99%

See 3 more Smart Citations

Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review

Pan

Lee

Nambudiri

2022

Therapeutic Advances in Vaccines and Immunotherapy

View full text Add to dashboard Cite

Herpes zoster (HZ) is a neurocutaneous disease that causes significant morbidity worldwide. The disease is caused by the reactivation of the varicella-zoster virus (VZV), which leads to the development of a painful, vesicular rash and can cause complications such as post-herpetic neuralgia and vision loss. Globally, the incidence of HZ is increasing, and it incurs billions in cost annually to the healthcare system and to society through loss of productivity. With the advent of effective vaccines such as the live attenuated vaccine, Zostavax®, in 2006, and more recently the adjuvant recombinant subunit vaccine, Shingrix®, in 2017, HZ has become a preventable disease. However, access to the vaccines remains mostly limited to countries with developed economies, such as the United States and Canada. Even among countries with developed economies that license the vaccine, few have implemented HZ vaccination into their national immunization schedules due to cost-effectiveness considerations. In this review, we discuss the currently available HZ vaccines, landscape of HZ vaccine guidelines, and economic burden of disease in countries with developed and developing economies, as well as barriers and considerations in HZ vaccine access on a global scale.

show abstract

“… 88 The RZV vaccine was licensed as of 2018, and in 2021, it was recommended for use in the national vaccine schedule. 20 …”

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Vaccine Administration and Special Considerationsmentioning

confidence: 99%

See 2 more Smart Citations

Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review

Pan

Lee

Nambudiri

2022

Therapeutic Advances in Vaccines and Immunotherapy

View full text Add to dashboard Cite

show abstract

“…Prior to this recommendation, some IMID groups, including adults with RA and those anticipating immunosuppression were recommended to receive RZV (2). Other countries have varying RZV recommendations for IMID populations (29). However, no clinical trials of RZV specific to IMID patients have been initiated.…”

Section: Discussionmentioning

confidence: 99%

Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults With Immune‐Mediated Inflammatory Diseases in the US

Leung

Anderson

Dooling

et al. 2022

Arthritis & Rheumatology

View full text Add to dashboard Cite

Objective Persons with immune‐mediated inflammatory diseases (IMIDs) are at an increased risk of herpes zoster (HZ). In 2018, the Centers for Disease Control and Prevention recommended a highly efficacious vaccine, recombinant zoster vaccine (RZV), for prevention of HZ in immunocompetent patients ≥50 years of age. This study was undertaken to estimate RZV vaccination among adults ages ≥50 years with IMIDs during 2018–2019 and to examine possible vaccine‐related flares following RZV. Methods We identified a cohort of IMID patients using medical claims data from the IBM MarketScan (ages 50–64 years) and Centers for Medicare and Medicaid Services Medicare (ages ≥65 years) databases. Presumed flares were defined as hospitalization/emergency department visit for their respective IMIDs, or steroid treatment with a short‐acting oral glucocorticoid or parenteral glucocorticoid injection. We conducted a self‐controlled case series (SCCS) analysis to examine a temporal association between RZV and flares. Results Among enrollees with IMIDs, 14.8% of 55,654 MarketScan enrollees and 43.2% of 160,545 Medicare enrollees received ≥1 dose of RZV in 2018–2019. Two‐dose series completion rates were 76.6% in MarketScan enrollees and 85.4% in Medicare enrollees. In the SCCS analysis, 10% and 13% developed flares in the control window, compared to 9% and 11–12% in the risk window following 1 or 2 doses of RZV among MarketScan and Medicare enrollees, respectively. We found no statistically significant increase in flares following RZV administration for any IMID in either age group following RZV dose 1 or dose 2. Conclusion We did not find an increase in presumed flares following RZV vaccination. Among adults ages ≥50 years with IMIDs, a substantial proportion received RZV compared to general zoster coverage estimates, and series completion rates were high.

show abstract

Assessing herpes zoster vaccine efficacy in patients with diabetes: A community‐based cohort study

Kornelius,

Lo,

Huang

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

The effectiveness of herpes zoster (HZ) vaccines in patients with diabetes over the age of 50 remains an active area of research. Utilizing a real‐world database from the US community, this study spanning from 2006 to 2023, aimed to evaluate the impact of HZ vaccination on newly diagnosed diabetes patients who received an HZ vaccination within 1 year of diagnosis. Exclusion criteria were established to omit patients with immune deficiencies. The cohort consisted of 53 885 patients, with an average age of 63.5 years, including 43% females and 58% whites. After implementing 1:1 propensity score matching for age, sex, race, comorbidities, diabetes medication, and hemoglobin A1c to ensure comparability, the study population was further stratified into four groups: N1 comparing any HZ vaccination to non‐HZ vaccination (53 882 matched pairs), N2 for Shingrix versus non‐HZ vaccination (16 665 matched pairs), N3 for Zostavax versus non‐HZ vaccination (12 058 matched pairs), and N4 for Shingrix versus Zostavax (11 721 matched pairs). Cox proportional hazards regression analysis revealed a hazard ratio (HR) for HZ incidence post any HZ vaccination of 0.92 (95% confidence interval [CI]: 0.83–1.01). Additional analyses yielded HRs of 1.12 (95% CI: 0.93–1.34) for Shingrix versus non‐HZ vaccine, 1.02 (95% CI: 0.86–1.20) for Zostavax versus non‐HZ vaccine, and 1.06 (95% CI: 0.87–1.29) for Shingrix versus Zostavax. Subgroup analyses across age, sex, and follow‐up duration also showed no significant differences. These findings underscore the lack of a significant benefit from HZ vaccination in newly diagnosed diabetes patients aged over 50, highlighting the necessity for further prospective research.

show abstract

A practitioner’s guide to the recombinant zoster vaccine: review of national vaccination recommendations

Cited by 25 publications

References 31 publications

Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review

Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review

Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults With Immune‐Mediated Inflammatory Diseases in the US

Assessing herpes zoster vaccine efficacy in patients with diabetes: A community‐based cohort study

Contact Info

Product

Resources

About